Combinatorial treatment for unresectable unicentric Castleman disease.
Meera MohanJames C MeekMary Elizabeth MeekRalph BroadwaterDaisy AlapatFrits van RheePublished in: European journal of haematology (2021)
Unresectable, symptomatic unicentric Castleman disease (UCD) can represent a formidable therapeutic challenge. UCD masses are often highly vascularized offering the opportunity for therapeutic embolization. Herein, we report on 6 patients in which therapeutic embolization was combined with other medical interventions including surgery (n = 3), rituximab (n = 6), cryoablation (n = 2), and chemotherapy (n = 3). Five patients had significant tumor volume reductions (median: 83.2%; range: 76.7-100). All five responding patients had resolution of symptomatology. There were no serious complications in the patients who received embolization and proceeded to surgery. In conclusion, effective disease and symptom control can be obtained in patients with symptomatic, unresectable UCD by combining different therapeutic interventions.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- minimally invasive
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- locally advanced
- physical activity
- risk factors
- coronary artery disease
- magnetic resonance
- radiation therapy
- coronary artery bypass
- acute coronary syndrome
- patient reported
- liver metastases
- combination therapy